Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Sorafenib may stop the growth of cancer cells by blocking blood flow to the cancer and by
blocking some of the enzymes needed for cell growth. This phase II trial is studying how well
sorafenib works in treating patients with chemosensitive recurrent aggressive non-Hodgkin's
lymphoma